This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chaer, R. A. Articles by Mureebe, L. Search for Related Content PubMed PubMed Citation Articles by Chaer, R. A. Articles by Mureebe, L. Social Bookmarking                         What's this?

Platelet Function and Pharmacologic Inhibition

Department of Surgery, Division of Vascular Surgery, New York Presbyterian Hospital

Joseph A. Graham, DO

Division of Vascular Surgery, The University of Missouri at Columbia

Leila Mureebe, MD

New York Presbyterian Hospital, Columbia University Medical Center, 5141 Broadway, 3rd floor, Suite 169, New York, NY 10034; lm2242{at}columbia.edu

Platelets have traditionally been understood within the context of hemostasis and hemorrhagic disorders. However, with increasing procedures being performed in smaller vessels and with an increasing incidence of atherosclerosis, the often critical role platelets play is more evident. Platelets are no longer viewed as "scaffolding" for the events of the coagulation cascade but rather as important catalysts in hemostasis, thrombosis, and fibrinolysis. Improved understanding of platelet physiology has led to developments of pharmacologic adjuncts resulting in improved patency rates and improved patient outcomes. This review addresses the physiology of platelet function and the impact of new pharmacologic agents in percutaneous intervention.

Vascular and Endovascular Surgery, Vol. 40, No. 4, 261-267 (2006)
DOI: 10.1177/1538574406291794


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?